固定剂量复方右美沙芬-安非他酮：治疗难治性抑郁症（TRD）的一种希望。
Fixed dose combination dextromethorphan-bupropion: A hope for treatment resistant depression (TRD).
作者信息
Das Ranjan, Chakravarty Rajarshi, Gantait Varaha V, Bhattacharjee Subir
机构信息
Department of Psychiatry, IOP-COE, IPGMER, Kolkata, West Bengal, India.
Department of Psychiatry, Jhargram Govt. Medical College and Hospital, Vidyasagar Pally, Jhargram, West Bengal, India.
出版信息
Indian J Psychiatry. 2025 Jun;67(6):635-638. doi: 10.4103/indianjpsychiatry_315_25. Epub 2025 Jun 11.
BACKGROUND
Treatment resistant depression (TRD) has been identified as non-response to depression with adequate dose and trial of two antidepressant medications of different classes. Near about 30% depressive patients are TRD cases. Olanzapine-fluoxetine combination, rTMS, Intravenous ketamine and Electroconvulsive therapy have been till now studied in TRD. Dextromethorphan-bupropion is a newer antidepressant, which has been found to be effective, fast-acting, and well tolerated medicine for depression.
CASES AND CONCLUSION
We used this novel antidepressant in three cases of TRD, alone and with combination, and it showed satisfactory response within 2 weeks.
背景
难治性抑郁症（TRD）被定义为在足量使用两种不同类型的抗抑郁药物并经过足够疗程的治疗后仍无反应。近30%的抑郁症患者为难治性抑郁症病例。到目前为止，已经对奥氮平-氟西汀联合用药、重复经颅磁刺激（rTMS）、静脉注射氯胺酮和电休克治疗在难治性抑郁症中的应用进行了研究。右美沙芬-安非他酮是一种新型抗抑郁药，已被发现对抑郁症有效、起效快且耐受性良好。
病例与结论
我们在3例难治性抑郁症患者中单独或联合使用了这种新型抗抑郁药，患者在2周内均表现出令人满意的反应。
Zotero 插件